Diagnostic Tools for Lung and Mesothelioma Cancers to be Developed

In a recent article on Mesothelioma Cancer Diagnostic Tools, Rosetta Genomics, Ltd. announced that it has partnered with NYU Medical Center with the aim of developing a line of early detection diagnostic products for lung and Mesothelioma cancers.

The early detection test will mainly target over 45 million Americans who are at an increased risk of lung cancer due to smoking, as well as those who have been exposed to asbestos fibers. The test will utilize Rosetta Genomics' proprietary protocol to extract microRNAs from a simple blood draw.

"A test that will be able to detect cancer at an early stage using a simple blood draw will have far reaching implications on the fight against cancer," noted Dr. Harvey Pass, Professor and Chief, Division of Thoracic Surgery and Thoracic Oncology at NYU Medical Center. "MicroRNAs have been shown to hold great potential as effective biomarkers for various cancers, and I believe that NYU Medical Center's vast experience with lung cancer and Mesothelioma, coupled with Rosetta Genomics' expertise in the microRNA field, will allow us to successfully advance this much needed test forward."

Early Diagnosis of Mesothelioma By Testing Levels of Mesothelin in Pleural and Peritoneal Effusions

Mesothelioma researchers in Australia have announced that mesothelioma can be diagnosed at an early stage by testing levels of mesothelin in fluid taken from a pleural effusion or peritoneal effusion. http://www.cancerpage.com/news/article.asp?id=11098 Such effusions are a classic mesothelioma symptom and testing fluid from pleural and peritoneal effusions is often the first diagnostic test for suspected cases of mesothelioma.

According to the article in Cancerpage.com, the team of Australian researchers, led by Dr. Jenette Creaney, maintains that: "Measurement of mesothelin levels in effusions could facilitate earlier diagnosis."

The article also states: "Dr. Creaney and associates previously showed that serum levels of mesothelin had high specificity and moderate sensitivity for mesothelioma. Based on these findings, the US Food and Drug Administration has approved the use of serum levels of soluble mesothelin for disease monitoring in mesothelioma."

The possibility of a test that could detect mesothelioma at an early stage could extend and perhaps even save lives. Most cases of mesothelioma are diagnosed at advanced stages when the mesothelioma has already spread in sheets throughout the pleura or peritoneum.

We hope this break-through will lead to earlier mesothelioma diagnoses and ultimately a mesothelioma cure.